Serum Level of Soluble Intercellular Adhesion Molecule 1 in Patients with Chronic Liver Disease Related to Hepatitis C Virus: A Prognostic Marker for Responses to Interferon Treatment

Capra, Franco; Maria, E. De; Lunardi, Claudio; Marchiori, L; Mezzelani, Paolo; Beri, Ruggero; Gabrielli, G

doi:10.1086/315265

Cited by 35 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, our findings appear in agreement with literature data and suggest that VCAM-1, which is considered to reflect the degree of liver fibrosis (25,28) and ICAM-1 levels, markers of liver inflammation, have significantly decreased in HCV patients with normal ALT levels following interferon administration (28,42,46,47). However, the relationship between ICAM-1, VCAM-1 and ALT values does not implicate a direct involvement of these adhesion molecules in physiopathology of hepatocellular damage, but it could only reflect the activation of undergoing immunological mechanisms.…”

Section: Discussionsupporting

confidence: 91%

Adhesive molecules and inflammatory markers among hepatitis C virus Saudi patients

Al-Jiffri

2017

Electron J Gen Med

View full text Add to dashboard Cite

Background:Currently, about 2% of population are affected with hepatitis C worldwide, chronic hepatitis C (CHC) is the major cause of hepatic cirrhosis and referral for liver transplant. However, there is a high need for noninvasive methods for assessment of hepatocellular damage. Objective: The purpose of this study was to determine the strength of the association between adhesive molecules and inflammatory markers among hepatitis C virus Saudi patients. Methods: One hundred patients with chronic hepatitis C virus infection(64 males and 36 females, their age ranged from 28 to 53 years with circulating anti-HCV antibodies were equally categorized into two study groups: patients with CHC and patients with liver cirrhosis (LC). Also, one fifty healthy subjects were included as healthy controls. Serum alanine aminotransferase (ALT), soluble intercellular adhesion molecule1 (sICAM-1); Soluble vascular adhesion molecule 1(sVCAM-1); Soluble E-selectin(s-E-selectin) and Tumor necrosis factor-alpha (TNF-α) were assayed for all participants. Results: We observed elevation with regard to the healthy controls group in the parameters of ALT, sICAM-1, sVCAM-1, s-E-selectin and TNF-α for patients with CHC and patients with liver cirrhosis (LC). Also, a significant positive correlation between serum TNF-α, sICAM-1, sVCAM-1 and ALT values was detected. Conclusion:In conclusion, our results confirm that, in patients with chronic virus hepatitis and liver cirrhosis there is a significant positive correlation between serum TNF-α, sICAM-1, sVCAM-1 and ALT values. These findings suggest that serum TNF-α levels could be used as a sensitive predictor of liver inflammation, while serum ICAM-1 can be considered as a marker of hepatic necrosis and inflammatory activity in chronic hepatitis, while serum VCAM-1 is an indicator for the severity of liver cirrhosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Adhesive molecules and inflammatory markers among hepatitis C virus Saudi patients

Al-Jiffri

2017

Electron J Gen Med

View full text Add to dashboard Cite

show abstract

“…Furthermore, a second histological score according to Desmet et al [27] was calculated, which distinguishes between grading (score 0-18), obtained by the sum of histological changes expressed by Knodell's numerical scoring system (periportal necrosis, intralobular degeneration and portal inflammation), and staging, an expression of fibrosis (score 0-4). Histological diagnosis was performed according to Desmet et al [27]: minimal chronic hepatitis (grading 1-3), mild chronic hepatitis (grading 4-8), moderate chronic hepatitis (grading 9-12) or severe chronic hepatitis (grading [13][14][15][16][17][18]. If staging was 3 (independently of grading), the classification was hepatitis with severe fibrosis; if staging was 4, the classification was liver cirrhosis.…”

Section: Methodsmentioning

confidence: 99%

“…This expression favours the adhesion of T lymphocytes with surface lymphocyte functionassociated antigen-1 on hepatocytes and may trigger an immune reaction and maintain chronic inflammation [5,6]. Elevated serum levels of a soluble form of ICAM-1 (sICAM-1) have been reported in patients with chronic liver disease of alcoholic [7], autoimmune [8,9] and viral etiology, particularly hepatitis C virus (HCV), as well as changes in these levels after treatment with ·-IFN [10][11][12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Montalto

Giannitrapani²,

Soresi³

et al. 2003

Intervirology

View full text Add to dashboard Cite

Objectives: Intercellular adhesion molecule-1 (ICAM-1) plays a fundamental role during liver inflammation. In fact, weak ICAM-1 expression is physiologically restricted to the endothelium of portal vessels and to sinusoidal lining cells, but it becomes markedly evident on sinusoidal lining cells and at the surface of hepatocytes during inflammatory liver diseases. The aim of this study was to evaluate the behaviour of soluble ICAM-1 (sICAM-1) in chronic hepatitis C (CH-C) patients with persistently normal aminotransferase in comparison with patients with CH-C and elevated aminotransferase, and its changes during α-interferon (IFN) therapy. Immunohistochemical localization of ICAM-1 was also performed on liver tissue specimens of both groups. Methods: Sixty subjects were divided into 3 groups: group A included 19 patients with CH-C and persistently normal aminotransferase; group B included 21 patients with CH-C and persistently elevated aminotransferase levels, and group C included 20 healthy subjects representing the control group. The first two groups were treated with recombinant α-IFN 2b at a dose of 6 MU 3 times a week for 3 months and followed up with 3 MU 3 times a week for another 3 months. Results: Baseline values of serum ICAM-1 in groups A and B were significantly higher than those in group C (p < 0.0001). The median baseline value of sICAM-1 in group A (525.0 ng/ml) was lower than that of group B (561.0 ng/ml), but the difference was not statistically significant. Furthermore, there was a trend toward higher ICAM-1 values as histological severity increased (Mantel-Haenszel χ² 8.8, p < 0.003). Post-treatment sICAM-1 serum values showed a marked decrease in both groups, but only among responder patients, while ICAM-1 levels were unchanged in non-responders. Immunohistochemical localization showed no staining for ICAM-1 in normal liver specimens, while there was a quite similar staining for ICAM-1 in the two groups of patients, consistent with an inflammatory process. Conclusions: This study shows that circulating ICAM-1 levels in most patients with CH-C and persistently normal aminotransferase are higher than those in a control group and the fact that ICAM-1 molecules are also expressed on the hepatocyte membrane suggests that they could play an important role, in association with other molecules, in the intercellular adhesion processes during the induction and maintenance phases of the immune response. In both groups, only patients responding to α-IFN therapy showed a marked decrease in serum ICAM-1 below baseline values.

show abstract

“…The concentration of sICAM-1 decreased significantly only in responders during the first 3 months of therapy (11). The probability of response to treatment was much higher in the group showing a decrease of sICAM-1 than in the patients who did not show such a decrease.…”

Section: Discussionmentioning

confidence: 82%

“…The probability of response to treatment was much higher in the group showing a decrease of sICAM-1 than in the patients who did not show such a decrease. A "longitudinal" evaluation of serum levels of sICAM-1 in the first period of treatment is particularly useful in the identification of patients with a significantly high probability of responding to treatment (11). However, most studies focus on the sICAM-1 values after three months or at six-month intervals after stopping treatment, for a total two-year follow-up (12).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of prognostic value of cell adhesion molecules in chronic hepatitis C therapy

Abdallah¹,

Morsi²,

Hamed³

et al. 2010

J. Venom. Anim. Toxins incl. Trop. Dis

View full text Add to dashboard Cite

Abstract:The most reliable determination of severity and prognosis in chronic viral hepatitis is the histological staging of the disease, which comprises an invasive procedure and is often not well accepted by patients. The search for alternative non-invasive methods is mandatory especially in follow-ups after initial assessment by biopsy. The aim of this study was to evaluate the role of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in patients under interferon alpha therapy whether responsive or non-responsive to therapy. Thirty chronic hepatitis C patients (CHC) under combined therapy of interferon-α with ribavirin, whether responsive or non-responsive, were included in the study as well as ten healthy controls. Serum VCAM-1 and ICAM-1 levels were calculated using commercial enzyme linked immunosorbent assay (ELISA) kits. Before the therapy, sICAM-1 and sVCAM-1 levels were significantly higher among CHC patients (96.9 ± 39.74 and 679.4 ± 218.98 ng/mL, respectively) than in the control group (14.3 ± 4.32 and 108.9 ± 49.21 ng/mL, respectively), (p < 0.05 for both). They were higher among non-responsive than in responsive patients. Comparisons in soluble ICAM-1 (sICAM-1) levels of responsive persons during treatment revealed a statistically significant increase at baseline (81.27 ± 25.797) versus its value after one month (52.33 ± 12.76), p < 0.05 and after three months (49.67 ± 14.42), p < 0.05. However, no statistically significant difference was detected between one and three-month sICAM-1 levels post-therapy commencement (p = 0.055). Also, no statistically significant difference was detected between sVCAM-1 levels at baseline (521.47 ± 137.29) versus three months after therapy initiation (517.53 ± 130.6), p = 0.854. The occurrence of a significant decrease in sICAM-1 level as early as one month after therapy in responsive patients only allows us to conclude that sICAM-1 could be used as an early marker in CHC patients under interferon therapy to predict prognosis and guide the treatment, whereas sVCAM-1 does not present any difference between the studied groups.

show abstract

Serum Level of Soluble Intercellular Adhesion Molecule 1 in Patients with Chronic Liver Disease Related to Hepatitis C Virus: A Prognostic Marker for Responses to Interferon Treatment

Cited by 35 publications

References 32 publications

Adhesive molecules and inflammatory markers among hepatitis C virus Saudi patients

Adhesive molecules and inflammatory markers among hepatitis C virus Saudi patients

Circulating Intercellular Adhesion Molecule-1 in Chronic Hepatitis C Patients with Normal or Elevated Aminotransferase before and after Alpha-Interferon Treatment

Evaluation of prognostic value of cell adhesion molecules in chronic hepatitis C therapy

Contact Info

Product

Resources

About